Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus
CA 2315736 A1 · Owner: Horizoe, Tatsuo · Inventors: Harada, Hitoshi; Horizoe, Tatsuo; Inoue, Takashi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Preventives/remedies of a novel type for diabetes and complications thereof based on the adenosine A2 receptor antagonism. Purine derivatives represented by general formula (I), pharmacologically acceptable salts thereof or hydrates of the same have adenosine A2 receptor antagonism and are useful in preventing and treating diabetes and its complications. Moreover adenosine A2 receptor , antagonists being different from the above compounds in structure for example , KW6002 are also useful in preventing and treating diabetes and its complications. In formula (I), W represents -CH2CH2- -CH=CH- or -CC-; and R1 , represents KW6002.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 24, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 24, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 24, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.